Article Versions Notes

Qin K, Wang K, Li S, Hong L, Padmakumar P, Waree R, Hubert SM, Le X, Vokes N, Rai K, et al. Clinical Benefit from Docetaxel +/− Ramucirumab Is Not Associated with Mutation Status in Metastatic Non-Small-Cell Lung Cancer Patients Who Progressed on Platinum Doublets and Immunotherapy. Cancers. 2024; 16(5):935. https://doi.org/10.3390/cancers16050935

Qin, Kang, Kaiwen Wang, Shenduo Li, Lingzhi Hong, Priyadharshini Padmakumar, Rinsurongkawong Waree, Shawna M. Hubert, Xiuning Le, Natalie Vokes, Kunal Rai, and et al. 2024. "Clinical Benefit from Docetaxel +/− Ramucirumab Is Not Associated with Mutation Status in Metastatic Non-Small-Cell Lung Cancer Patients Who Progressed on Platinum Doublets and Immunotherapy" Cancers 16, no. 5: 935. https://doi.org/10.3390/cancers16050935

Qin, K., Wang, K., Li, S., Hong, L., Padmakumar, P., Waree, R., Hubert, S. M., Le, X., Vokes, N., Rai, K., Vaporciyan, A., Gibbons, D. L., Heymach, J. V., Lee, J. J., Woodman, S. E., Chung, C., Jaffray, D. A., Altan, M., Lou, Y., & Zhang, J. (2024). Clinical Benefit from Docetaxel +/− Ramucirumab Is Not Associated with Mutation Status in Metastatic Non-Small-Cell Lung Cancer Patients Who Progressed on Platinum Doublets and Immunotherapy. Cancers, 16(5), 935. https://doi.org/10.3390/cancers16050935